Background: Recent evidence suggests that hydrogen sulfide is capable of mitigating the degree of cellular damage associated with ischemia-reperfusion injury. The purpose of this study was to determine whether it is protective in skeletal muscle. Methods: This study used both in vitro (cultured myotubes subjected to sequential anoxia and normoxia) and in vivo (mouse hind-limb ischemia followed by reperfusion) models in which hydrogen sulfide (0 to 1000 M) was delivered before the onset of oxygen deficiency. Injury score and apoptotic index were determined by analysis of specimens stained with hematoxylin and eosin and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling, respectively. Results: In vitro, hydrogen sulfide reduced the apoptotic index by as much as 99 percent (p ϭ 0.001), with optimal protection conferred by raising intravascular hydrogen sulfide to 10 M. In vivo, 10 M hydrogen sulfide delivered before 3 hours of hind-limb ischemia followed by 3 hours of reperfusion resulted in protection against ischemia-reperfusion injury-induced cellular changes, as evidenced by significant decreases in injury score and apoptotic index (by as much as 91 percent; p ϭ 0.001). These findings were consistent at 4 weeks after injury and reperfusion. Conclusion: These findings confirm that the preischemic delivery of hydrogen sulfide limits ischemia-reperfusion injury-induced cellular damage in myotubes and skeletal muscle and suggests that, when given in the appropriate dose, this molecule may have significant therapeutic applications in multiple clinical scenarios. (Plast.
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schemia-reperfusion injury is a poorly understood phenomenon. Although it is intuitive that cellular injury occurs when there is an insufficient oxygen supply, injury is further exacerbated on restoration of tissue oxygen supply. 1 Tissue damage occurs by means of the generation of oxidative stress and a subsequent inflammatory response that ultimately leads to microvascular thrombosis and tissue necrosis. 2, 3 Ischemia-reperfusion injury is a major source of morbidity and mortality in myriad clinical scenarios, including solid organ transplantation, myocardial infarction, and ischemic cerebral vascular accidents. 4 It is also a cause of irreversible damage to skeletal muscle made ischemic either electively (e.g., free tissue transfer) or as a result of unplanned hypoperfusion (e.g., lower extremity arterial occlusion).
Because of its high metabolic activity, skeletal muscle is acutely susceptible to reperfusion injury after even brief periods of ischemia. Currently, the only established means of minimizing the ischemic injury in skeletal muscle is to achieve rapid reperfusion, thereby minimizing the duration of the ischemic period. A therapeutic intervention that changes the biochemical environment during the ischemic period (and immediately after reperfusion) and results in amelioration of subsequent cellular damage would be of significant benefit. Accordingly, a number of compounds have been evaluated, but none has yet been translated into clinical practice. 5, 6 Hydrogen sulfide has historically been thought of as an environmental toxic gas 7 but is now known to be an endogenous signaling molecule 8 in the gasotransmitter family, along with nitric oxide and carbon monoxide. 9, 10 Recently, several authors have reported the cytoprotective effects of hydrogen sulfide in cardiac, neurologic, and hepatic models of ischemia-reperfusion injury. [11] [12] [13] [14] The potential cytoprotective effect of hydrogen sulfide in skeletal muscle, however, has not yet been broadly evaluated. The purpose of this study was to explore the efficacy of hydrogen sulfide in reducing ischemia-reperfusion injury in skeletal muscle.
MATERIALS AND METHODS

Myotube Differentiation
Murine myoblasts (ATCC, Manassas, Va.) were cultured in Dulbecco's Modified Eagle Medium (Mediatech, Manassas, Va.) supplemented with 10% fetal bovine serum (JR Scientific, Woodland, Calif.) and 1% penicillin/streptomycin (Mediatech), plated into chamber slides (Nunc, Rochester, N.Y.), and differentiated into myotubes by means of exposure to media containing 2% horse serum (PML Microbiologicals, Wilsonville, Ore.). All studies were performed on passage 4 cells, 4 days after exposure to horse serum.
Mice
Eight-week-old male C57Bl/6 mice were used for all in vivo studies (Jackson Laboratory, Bar Harbor, Me.). All animal care and experimental procedures were performed in compliance with the Guide for the Care and Use of Laboratory Animals 15 and were approved by the Weill Cornell Medical College Institutional Animal Care and Use Committee.
Hydrogen Sulfide Donor Modalities
Exposure to gaseous hydrogen sulfide was conducted in a custom-built environmental chamber. To obtain a final atmosphere containing 150-ppm hydrogen sulfide and 15% oxygen, 500-ppm hydrogen sulfide (Scott Specialty Gases, Plainfield, N.J.) was mixed with room air using a two-channel gas proportioner (Aalborg, Orangeburg, N.Y.) at a total rate of 1 liter/minute. Hydrogen sulfide and oxygen content of the environmental chamber were measured using a portable gas monitor (Thermo Fisher Scientific, Inc., Waltham, Mass.)
For both the in vitro and in vivo studies, the hydrogen sulfide donor was sodium hydrogen sulfide (Alfa Aesar, Ward Hill, Mass.) dissolved in sterile phosphate-buffered saline (EMD Chemicals, Gibbstown, N.J.), with a final pH of 8.5.
In Vitro Myotube Anoxia-Normoxia Studies
Myoblasts were plated onto chamber slides (1 ϫ 10 4 cells per well), and the following day the media was changed to that which contained horse serum to facilitate differentiation from myoblasts into myotubes. Cells were then treated with media containing varying concentrations of sodium hydrosulfide (0, 0.1, 1.0, 10, 100, and 1000 M) and allowed to equilibrate for 20 minutes (the pH of the media, 8.5, did not change with addition of sodium hydrosulfide). The cells were then subjected to 1, 3, or 5 hours of anoxia (0% oxygen) followed by 3 hours of normoxia (21% oxygen). A separate sample of myotubes were treated with the same amount of sodium hydrosulfide-containing media and was kept at 21% oxygen as a normoxic control. Myotubes were then fixed in 4% paraformaldehyde (Alfa Aesar) and stored at -20°C. All experiments were repeated in triplicate.
Murine Hind-Limb Ischemia-Reperfusion Studies
Forty-two mice were used in this study. Mice were anesthetized by means of intraperitoneal injection of ketamine (80 mg/kg) and xylazine (60 mg/kg), and treated with either inhaled gaseous hydrogen sulfide or intravenously injected sodium hydrosulfide. Mice exposed to gaseous hydrogen sulfide were placed in the chamber as described above and exposed to 150 ppm for 20 minutes and then returned to room air, whereas control animals received room air at the same flow rate (n ϭ 3 for each of the two groups). Mice treated with sodium hydrosulfide underwent intravenous injection of 200 l of phosphate-buffered saline containing between 0.0098 and 98 g of dissolved sodium hydrosulfide that would increase the total blood volume (estimated as 7 percent of 25 g, or 1.75 ml) to a desired final concentration of 0, 0.1, 1, 10, 100, or 1000 M (n ϭ 6 for each of the six groups). Figure 1 summarizes the time line for hydrogen sulfide delivery.
Hind-limb ischemia was performed by applying a tourniquet superior to the greater trochanter. The contralateral leg served as a nonischemic Volume 126, Number 6 • Therapeutic Metabolic Inhibition control. After 3 hours of ischemia, the tourniquet was removed and the ischemic limb was reperfused for 3 hours. At that time, the mice were killed according to institutional protocol, and the gastrocnemius muscle was harvested and processed. An additional series of mice underwent the same hind-limb ischemia procedure after being treated with 0 or 10 M hydrogen sulfide 20 minutes before the onset of 3 hours of ischemia (n ϭ 6 for each of the two groups), and were allowed to reperfuse for 4 weeks, at which time they were killed and the tissue was processed as below.
Tissue Processing
Excised muscle was washed in phosphate-buffered saline and fixed in 10% buffered formalin for 24 hours, dehydrated, and embedded in paraffin. Ten-micrometer sections were stained with hematoxylin and eosin.
Terminal Deoxynucleotidyl TransferaseMediated dUTP Nick End Labeling Assay
The terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) assay was used to assess apoptosis in both models. The In Situ Cell Death Detection Kit (Roche Applied Sciences, Indianapolis, Ind.) with Prolong Gold Antifade reagent with 4=,6-diamidino-2-phenylindole counterstain (Invitrogen, Carlsbad, Calif.) was used according to the manufacturer's instructions. Briefly, slides with either myotubes (from in vitro studies) or sections of gastrocnemius (from in vivo studies) were permeabilized with 0.1% Triton X-100 (MP Biomedicals, Solon, Ohio) and 0.1% citric acid (Mallinckrodt, Hazelwood, Mo.), the TUNEL solution was applied for 1 hour, and counterstain was applied.
Determination of Injury Score
The injury score was determined based on a protocol derived from that which was established by McCormack et al. 16 Four random photomicrographs were taken of each hematoxylin and eosinstained section, and based on the proportion of injured cells (defined by ragged cellular borders, vacuolization, lymphocytic infiltration, or rhabdomyolysis), a numerical value between 0 and 10 was determined. Values are presented as mean Ϯ SEM.
Determination of Apoptotic Index
TUNEL-stained myotubes and muscle sections were analyzed by means of florescent microscopy. Apoptotic index was determined by quantifying the average number of TUNEL-positive myocyte nuclei divided by the number of TUNEL-negative/4=,6-diamidino-2-phenylindole-positive myocyte nuclei across five random high-power fields (200ϫ) by two blinded observers (no other types of cells, such as fibroblasts or endothelial cells, were factored into the calculation). Fluorescent microscopy was performed with an upright microscope with a 4=,6-diamidino-2-phenylindole/fluoresecent isothiocyanate filter (Nikon, Tokyo, Japan). Values are presented as mean Ϯ SEM.
Statistical Analysis
Statistical significance was determined by first performing a square root transformation to the data to correct for heteroscedasticity. Subsequently, a series of independent measures t tests was performed, maintaining a family error rate of ␣ ϭ 0.05.
RESULTS
In Vitro Studies
To evaluate the cytoprotective effects of hydrogen sulfide on myotubes, cells were cultured as described above, treated with increasing concentrations of sodium hydrosulfide, and then exposed to varying lengths of anoxia (ischemia) followed by 3 hours of normoxia (reperfusion). Fluorescent TUNEL assay demonstrated a cytoprotective effect of preischemic treatment of myotubes with sodium hydrosulfide across all doses tested when compared with untreated controls. In myotubes subjected to 1 hour of anoxia followed by 3 hours (Fig. 2) . In myotubes subjected to 3 hours of anoxia followed by 3 
In Vivo Studies
The administration of preischemic gaseous hydrogen sulfide (150 ppm) resulted in the preservation of normal tissue and cellular architecture with minimal extracellular edema, and a near complete absence of intracellular vacuolization compared with untreated controls (Fig. 3) .
For in vivo studies in which the hydrogen sulfide donor modality was sodium hydrosulfide, the amount of ischemia-reperfusion-induced injury was decreased across the entire dose range. The ischemic hind-limb muscle from mice that had been treated with preischemic sodium hydrosulfide showed preservation of normal muscle architecture with minimal fiber separation, virtually absent edema, and significantly reduced intracellular vac- Volume 126, Number 6 • Therapeutic Metabolic Inhibition uole formation compared with untreated controls (Fig. 4) . The injury score for muscle that had not been treated with sodium hydrosulfide was 4.8 Ϯ 0.5, 5.3 Ϯ 0.2 for 0.1 M (p ϭ 0.347), 1.6 Ϯ 0.4 for 1 M (p ϭ 0.004), 1.1 Ϯ 0.3 for 10 M (p ϭ 0.004), 1.3 Ϯ 0.2 for 100 M (p Ͻ 0.001), and 1.8 Ϯ 0.2 for 1000 M (p ϭ 0.001). Analysis of the TUNEL assay revealed that at the 0.1-M dose the apoptotic index was reduced by 53 percent compared with the untreated control (p ϭ 0.012), at the 1-M dose the apoptotic index was reduced by 71 percent (p ϭ 0.001), at the 10-M dose the apoptotic index was reduced by 91 percent (p ϭ 0.001), at the 100-M dose the apoptotic index was reduced by 84 percent (p ϭ 0.008), and at the 1000-M dose the apoptotic index was reduced by 24 percent (p Ͼ 0.050). There were no significant differences in tissue or cellular architecture or number of apoptotic cells between nonischemic muscle that had been treated with sodium hydrosulfide versus non-sodium hydrosulfidetreated, nonischemic controls (data not shown).
In mice that underwent 3 hours of ischemia and 4 weeks of reperfusion, treatment with sodium hydrosulfide 20 minutes before the onset of ischemia resulted in muscle with significantly less fiber separation and intracellular vacuolization compared with ischemic and reperfused muscle from non-sodium hydrosulfide-treated mice (Fig. 5) . Similarly, the injury score for non-sodium hydrosulfide-treated mice was 2.6 Ϯ 0.4, and was reduced to 0.5 Ϯ 0.1 in those that had been treated with 10 M sodium hydrosulfide (p Ͻ 0.001).
DISCUSSION
Although ischemia-reperfusion injury remains a significant source of morbidity and mortality across an array of medical and surgical specialties, there has been little progress made toward the development of translatable therapeutic interventions that might ameliorate this physiologic phenomenon. Although many clinical ischemic events remain "unplanned," there are numerous scenarios where an obligatory ischemic interval is anticipated (including cardiopulmonary bypass, solid organ allotransplantation, and microsurgical free tissue transfer). Attempts to minimize morbidity associated with these scenarios have been largely limited to using cold temperatures and electrolyte solutions to decrease the cellular metabolism while the tissue remains ischemic. 17, 18 Despite these interventions, postoperative complications can result from even brief intervals of ischemia Muscle treated with gaseous hydrogen sulfide, 150 ppm, 20 minutes before 3 hours of ischemia followed by 3 hours of reperfusion (n ϭ 3 for each study group) (original magnification, 100ϫ). Injury score and apoptotic index based on hematoxylin and eosin-stained and TUNEL-stained images, respectively, calculated for nonischemic control muscle (above, left, and above, center), ischemic-reperfused muscle that had not been treated with hydrogen sulfide (center, left, and center, center), and ischemic-reperfused tissue that had been treated with preischemic 150-ppm hydrogen sulfide (below, left, and below, center). Note the preservation of normal muscle architecture following treatment with hydrogen sulfide (HS).
Plastic and Reconstructive Surgery • December 2010 followed by reperfusion. Furthermore, neither of these treatments has proven useful for scenarios in which the ischemic interval is unanticipated.
The ideal intervention would be simple, nontoxic, and efficacious in cases of both anticipated and unexpected ischemia. Although many pharmacologic interventions to ameliorate ischemiareperfusion injury have been proposed, none has proven ideal for use in clinical settings. 19 We believe that when administered in appropriate doses, hydrogen sulfide holds significant promise as a cytoprotective agent.
As our data demonstrate, sodium hydrosulfide conferred protection to muscle both in vitro and in vivo subjected to conditions of anoxia followed by normoxia. In vitro, when myotubes were treated with sodium hydrosulfide, significant protection was noted after as much as 5 hours of anoxia. In vivo, this protection was noted for an ischemic period of at least 3 hours in animals treated with hydrogen sulfide or sodium hydrosulfide. Importantly, this is well beyond the empirically established clinical limit of 2 hours of ischemia, after which point irreversible damage occurs in muscle tissue. 19 Furthermore, the interval of ischemia chosen in these series of experiments is considerably longer than the ischemic interval of 45 minutes to 1 hour chosen in many of the previous studies into the protective effects of hydrogen sulfide. 11-13,20 -22 This is significant because all cases of unanticipated tissue ischemia, and even most scenarios of anticipated tissue ischemia, will last longer than 1 hour. Thus, to make hydrogen sulfide treatment a translatable therapy, efficacy must be demonstrated after several hours of ischemia. We are currently investigating the maximal period of ischemia permissible when tissues are pretreated with sodium hydrosulfide. Furthermore, the length of the reperfusion period (either 3 hours or 4 weeks) was based on clinical relevance and prior experiments from our laboratory indicating that sufficient effect was present to allow for differences to be observed between treatment groups (data not shown).
Although this and many previous studies have focused on the "early" phase of ischemia-reperfusion injury, ours is one of the only studies to demonstrate that hydrogen sulfide treatment provides significant long-term protection. Skeletal muscle from animals killed 4 weeks after ischemia dem- Muscle treated with intravenous sodium hydrosulfide 20 minutes before 3 hours of ischemia followed by 3 hours of reperfusion (n ϭ 6 for each study group) (original magnification, 100ϫ). Injury score and apoptotic index based on hematoxylin and eosin-stained and TUNEL-stained images, respectively, for nonischemic control muscle, ischemic-reperfused muscle that had not been treated with sodium hydrosulfide, and ischemic-reperfused tissue that had been treated with preischemic sodium hydrosulfide (representative photomicrograph of 10 M is shown). Note the preservation of normal muscle architecture following treatment with sodium hydrosulfide. Stars denote statistical significance (p Ͻ 0.05) compared with non-sodium hydrosulfidetreated control. HS, hydrogen sulfide.
Volume 126, Number 6 • Therapeutic Metabolic Inhibition onstrated histopathologic findings similar to those of animals killed 3 hours after injury. Thus, hydrogen sulfide is not merely "shifting" cellular and tissue damage several hours ahead (beyond the 3-to 5-hour window observed in most studies) but is in fact providing durable protection beyond the acute phase of ischemia-reperfusion injury (at least in locally affected tissues), and reinforces recent findings regarding the presence of latephase preconditioning. 22 Although many theories have been suggested to explain the protective effects of hydrogen sulfide, the exact mechanism by which this occurs remains unclear. The results of previous studies have suggested that hydrogen sulfide augments the body's innate antioxidant response. 23, 24 Hydrogen sulfide acts as a reversible inhibitor of cytochrome c oxidase, a key enzyme in oxidative phosphorylation. 23 By inducing partial, reversible blockade of the electron transport chain, it is possible that hydrogen sulfide leads to the generation of a nonlethal amount of reactive oxygen species, which thereby activate antioxidant defenses. According to this mechanism, hydrogen sulfide effectively "primes" the cell for more significant reactive oxygen species generation that occurs during a subsequent, sustained period of oxygen deficiency. Another proposed mechanism is that hydrogen sulfide functions as a reactive oxygen species scavenger, either directly or indirectly. Furthermore, hydrogen sulfide has been reported in several studies to activate both sarcolemmal (sK ATP ) and mitochondrial (mK ATP ) ATP-sensitive potassium channels. 10 However, the pathway by which each is thought to achieve cytoprotection is different. The opening of sK ATP channels leads to a net outflow of K ϩ and hyperpolarization, which reduces calcium entry into the cell. 25 In contrast, activation of the mK ATP channels leads to a net inflow of K ϩ , which leads to depolarization (which reduces Ca 2ϩ entry into the matrix) and alkalization of the matrix by means of the K ϩ /H ϩ antiporter and subsequent increase in reactive oxygen species (by means of complex I of the respiratory chain) that activate PKC⑀-2, the enzyme responsible for inhibiting mitochondrial permeability transition. 26 The level of hydrogen sulfide in the plasma under normal "physiologic" conditions has historically been controversial. 27 Although older studies measured sulfide concentrations between 10 and 300 M, one recent study concluded that circulating sulfide is negligible and thus may only act by means of autocrine or paracrine mechanisms. 28 These find- Muscle treated with intravenous sodium hydrosulfide 20 minutes before 3 hours of ischemia followed by 4 weeks of reperfusion, with injury score (n ϭ 6 for each study group) (original magnification, 100ϫ). Hematoxylin and eosin-stained images of nonischemic control muscle (above, left), ischemic-reperfused muscle that had not been treated with sodium hydrosulfide (center, left), and ischemic-reperfused tissue that had been treated with preischemic 10 M sodium hydrosulfide (below, left). Note the preservation of normal muscle architecture following treatment with sodium hydrosulfide. HS, hydrogen sulfide.
Plastic and Reconstructive Surgery • December 2010 ings were bolstered by another study in which hydrogen sulfide concentrations in mouse tissue measured approximately 15 nM, nearly an order of magnitude lower than both previously reported values, and lower than the concentrations required in the current study to confer protection. 29 Finally, we believe that the optimal route of hydrogen sulfide delivery is intravenous. Although our initial studies treated animals with gaseous hydrogen sulfide (the method described by Blackstone et al.), we found that this was an inconsistent method of delivery, and it has been reported to lead to pulmonary toxicity. 30 Furthermore, in the clinical setting, intravenous or even intraarterial delivery, depending on the desired application, would provide more focused treatment of target tissue, with less chance of pulmonary toxicity from gaseous hydrogen sulfide exposure. Although the current study used sodium hydrosulfide, others have used sodium hydrosulfide as the hydrogen sulfide donor. Given the protection conferred in this study, and in those using sodium hydrosulfide, it remains unclear which would be the optimal hydrogen sulfide donor for clinical use; direct comparisons of these hydrogen sulfide donors might provide useful insights. Future studies will address the optimal time course of delivery and whether hydrogen sulfide should be delivered as a bolus versus continual infusion.
